 |
|
UNC School of Pharmacy researchers create new synthetic heparin
September 24, 2007CHAPEL HILL -- Researchers at the University of North Carolina at Chapel Hill have patented a synthetic version of the drug heparin, called Recomparin, that is less complex chemically and should be easier to produce than previous forms.
Led by Jian Liu, Ph.D., scientists in the UNC School of Pharmacy discovered that they could remove a complex element from the heparin molecule without altering the drug's function. The component, a single sugar called iduronic acid, is difficult to replicate and was long thought to be an important contributor to heparin's function as an anticoagulant, Liu said.
"We proved we don't really need that structure for the anticoagulant effect," Liu said. "By eliminating the iduronic acid unit, we were able to reduce the structural complexity of the heparin molecule by approximately 50 percent."
Their findings were published in the Sept. 24, 2007, issue of the journal Chemistry & Biology. The study was supported by a grant from the National Institutes of Health.
Heparin is most commonly used to prevent clots from forming and restricting the flow of blood during and after procedures such as kidney dialysis, heart-bypass surgery, stent implantation and knee and hip replacement. The annual worldwide sales of heparin are estimated at $3 billion.
Heparin is a natural substance that is extracted from animal tissue, chiefly from cows and pigs. Outbreaks of diseases among livestock can interfere with production of the drug, driving up prices and tightening supplies.
"Synthesizing heparin, rather than extracting it from animals, gives us more control over its anticoagulant properties and creates a purer, safer, more reliable drug," Liu said.
Currently, synthetic forms of heparin are difficult to produce in large quantities because of the drug's complexity, resulting in expensive therapies that are not widely used, Liu said.
The simpler structure of Recomparin is likely to be easier to produce than other forms of synthetic heparin, Liu says. It is also expected to reduce dangerous side effects, such as uncontrolled bleeding, while providing the same benefits as naturally derived heparin.
The next step for Recomparin will be to find a company to license the drug and begin the process of getting Food and Drug Administration approval.
University of North Carolina at Chapel Hill
Their findings were published in the Sept. 24, 2007, issue of the journal Chemistry & Biology. The study was supported by a grant from the National Institutes of Health.
Heparin is most commonly used to prevent clots from forming and restricting the flow of blood during and after procedures such as kidney dialysis, heart-bypass surgery, stent implantation and knee and hip replacement. The annual worldwide sales of heparin are estimated at $3 billion.
Heparin is a natural substance that is extracted from animal tissue, chiefly from cows and pigs. Outbreaks of diseases among livestock can interfere with production of the drug, driving up prices and tightening supplies.
"Synthesizing heparin, rather than extracting it from animals, gives us more control over its anticoagulant properties and creates a purer, safer, more reliable drug," Liu said.
Currently, synthetic forms of heparin are difficult to produce in large quantities because of the drug's complexity, resulting in expensive therapies that are not widely used, Liu said.
The simpler structure of Recomparin is likely to be easier to produce than other forms of synthetic heparin, Liu says. It is also expected to reduce dangerous side effects, such as uncontrolled bleeding, while providing the same benefits as naturally derived heparin.
The next step for Recomparin will be to find a company to license the drug and begin the process of getting Food and Drug Administration approval.
University of North Carolina at Chapel Hill
Heparin Current Events and Heparin News RSSInvestigation of contaminated heparin syringes highlights medication safety issues
An outbreak of bloodstream infections appears to have been caused by the contamination of pre-filled heparin and saline syringes made by a single company.
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes
Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).
Patient safety advanced by revised heparin standards
Continuing to help ensure the identity, purity and quality of heparin, the U.S. Pharmacopeial (USP) Convention has revised written and physical standards for the widely used blood thinner.
'Artificial Golgi' may provide new insight into key cell structure
Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle.
Research highlights new approaches to prevent blood clots
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured.
Simple new method detects contaminants in life-saving drug
The blood-thinning drug heparin is highly effective when used to prevent and treat blood clots in veins, arteries and lungs, but earlier this year its reputation as a lifesaver was sullied when contaminated heparin products caused serious allergic reactions that led to a large number of deaths.
HORIZONS AMI will help set guidelines for drug and stent therapy
The HORIZONS AMI clinical trial measuring the safety and efficacy of the use of the medication bivalirudin compared to standard drug therapy - heparin and glycoprotein IIb/IIIa inhibitors -- in heart attack patients who receive angioplasty, found that after 1 year, use of bivalirudin resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding.
Safety of antithrombotic treatment in acute coronary syndromes
The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.
Chemists move closer toward developing safer, fully-synthetic form of heparin
Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions.
More Heparin Current Events and Heparin News Articles
 |
Chemistry and Biology of Heparin and Heparan Sulfate by Hari G. Garg (Editor), Robert J. Linhardt (Editor), Charles A. Hales (Editor) The chemistry, biochemistry and pharmacology of heparin and heparan sulfate have been and continue to be a major scientific undertaking - heparin and its derivative remain important drugs in clinical practice. Chemistry and Biology of Heparin and Heparan Sulfate provides readers with an insight into the chemistry, biology and clinical applications of heparin and heparan sulfate and examines their function in various physiological and pathological conditions. Providing a wealth of useful information, no other tome covers the diversity of topics in the field. Students, doctors, chemists, biochemists, and research scientists will find this book an invaluable source for updating their current knowledge of developments in this area. *... |
 |
Monoject Prefill I.V. Syringes - 12mL Syringe, Filled with 5mL 100U/mL Heparin Flush - 180 Per Case - Model SWD590125 by TYCO/KENDALL Saline and heparin flush syringes.Terminally sterile.Drug stopper quality plunger tip.Color-coded.Low breakforce.Latex and perservative free. |
 |
Drummond Hemato-Clad Mylar-Wrapped Hematocrit Tubes, Heparin-Coated, Red by Drummond Scientific Tubes, Microhemotocrit; Hematrocrit; Hemato-Clad; Drummond; Mylar wrapped glass; Heparin-coated; I.D. 1.1 to 1.2mm; 75mm length; 0.2mm thickness; Red |
 |
60 Minutes - The Wrong Medicine (March 16, 2008) Airdate: 03/16/08 As many as 100,000 people die each year from medical errors, and the newborn twins of actor Dennis Quaid and his wife Kimberly were nearly part of that statistic. When only days old, the babies were accidentally given the wrong dose of the blood thinner Heparin, and they nearly bled to death. Steve Kroft talks with the couple about their ordeal and about the issue of preventable medical mistakes. |
 |
B-d Vacutainer Plus Plastic Plasma Tubes 13 X 100 4.5ml Pst Tube W/ Polymer Gel And Lithium Heparin by Becton-dickinson B-D Vacutainer Plus Plastic Plasma Tubes 13 x 100 4.5mL PST Tube w/ Polymer Gel and Lithium Heparin : BD safety-engineered plastic blood collection tubes provide not only a clinically tested alternative to traditional glass tubes, but also offer you and your staff reduced risk of tube breakage and specimen spillage, thereby reducing risk of exposure to bloodborne pathogens, and are also in compliance with OSHA standards. Sterile. |
 |
Heparin HyperD M - Affinity Chromatography Resins, Pall Life Sciences - Model 20029-062 - Size: 5ml by Pall Blue Trisacryl M: Use for the purification of a wide variety of enzymes and proteins such as kinases, albumin, interferons, and some coagulation factors. The basic matrix is Trisacryl GF2000 resin, a macroporous non-ionic resin on which Cibacron blue is covalently immobilized. The resin has a particle size of 40-80um, giving it excellent mechanical stability. In addition, it can be used for more than 100 cycles of albumin separation from whole plasma. At the laboratory level, the separation speed allows several cycles to be performed in one day. The binding capacity was determined in PBS buffer with 5mg/mL albumin and is 10-15mg/mL for human albumin and 5-7mg/mL for bovine albumin. It has a working pH stability of 1-10 and pressure stability up to 3bar (45psi). Heparin HyperD M: Use to... |
 |
Heparin-Induced Thrombocytopenia, Fourth Edition (Fundamental and Clinical Cardiology) by Theodore E. Warkentin (Editor), Andreas Greinacher (Editor) Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most potentially devastating and frequent adverse drug reactions encountered by physicians. This Fourth Edition reinforces its standing as the leading guide to the accurate diagnosis and management of HIT by identifying key signs and symptoms of this disorder and providing clear intervention strategies, including detailed information on the use of alternative anticoagulants to manage these critical circumstances. Intended for those requiring an expert source of guidance for the quick detection and control of HIT, this reference: contains new chapters on novel pharmacotherapies, recent drug approvals, current dosing guidelines, and... |
|
Hate Me | |
|
Abbott Laboratories Heparin Lock 100 Units/Ml *sp - Sku ABT115270_BX25 by Abbott Laboratories Box of 25 | |
 |
Site Selection and Injection Techniques (Parenteral Medication Administration) (Volume Four) Also With: Concept Media (Primary Contributor) Discusses common intramuscular injection sites and essential assessment considerations. Concisely describes the techniques for administration of intra-muscular medications with emphasis on the displacement or Z-track method. Subcutaneous site selection is also discussed. Procedures, including specific techniques for insulin and heparin administration, are illustrated in detail. |
| © 2009 BrightSurf.com |